PBAC's latest decision on Romiplostim and eltrombopag: Recommended with restriction (2022). Considered for Treatment of immune thrombocytopenia (ITP) in adults and children. The submission reviews extensions to current PBS restrictions including sequential use between the two TPO-RAs, use as an alternative to splenectomy, paediatric use, and platelet count criteria for treatment initiation and continuation.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2022
Submissions
1
2022 → 2022
Eligible population
Adults and children with chronic immune thrombocytopenia (ITP) who have failed or are intolerant to corticosteroids and immunoglobulins; includes both splenectomised and non-splenectomised patients.
Therapy area
Haematology
Line of therapy
Second-line
Evidence base
Registry
Comparator
not applicable — this is a restriction review, not a new drug submission with economic comparison
Economic model
not-modelled
Eligible patients/year
10
ICER note
This is a restriction review of existing PBS listings (2009–2014). No new economic evaluation or ICER is presented; the submission addresses clinical practice updates and safety/efficacy reassessment.